Literature DB >> 20460894

Cytochrome P450 2D6 as a model antigen.

Urs Christen1, Martin Holdener, Edith Hintermann.   

Abstract

Cytochrome P450 2D6 (CYP2D6) has been identified as the major autoantigen in type 2 autoimmune hepatitis (AIH). However, because of a lack of appropriate animal models, the etiology of AIH is still poorly understood. We generated a mouse model for AIH using the human CYP2D6 as a triggering molecule for autoimmunity. We infected wild-type FVB mice with an adenovirus expressing human CYP2D6 (Ad-2D6) to break self-tolerance to the mouse CYP2D6 homologues. Ad-2D6-infected mice showed persistent features of liver damage including hepatic fibrosis, cellular infiltrations, focal-to-confluent necrosis and generation of anti-CYP2D6 antibodies, which predominantly recognized the identical immunodominant epitope recognized by LKM-1 antibodies from AIH patients. Interestingly, Ad-2D6 infection of transgenic mice expressing the human CYP2D6 (CYP2D6 mice) resulted in delayed kinetics and reduced severity of liver damage. However, the quantity and quality of anti-CYP2D6 antibodies was only moderately reduced in CYP2D6 mice. In contrast, the frequency of CYP2D6-specific CD4 and CD8 T cells was dramatically decreased in CYP2D6 mice, indicating the presence of a strong T cell tolerance to human CYP2D6 established in CYP2D6 mice, but not in wild-type mice. CYP2D6-specific T cells reacted to human CYP2D6 peptides with intermediate homology to the mouse homologues, but not to those with high homology, indicating that molecular mimicry rather than molecular identity breaks tolerance and subsequently causes severe persistent autoimmune liver damage. The CYP2D6 model provides a platform to investigate mechanisms involved in the immunopathogenesis of autoimmune-mediated chronic hepatic injury and evaluate possible ways of therapeutic interference. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460894      PMCID: PMC2883835          DOI: 10.1159/000282068

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  35 in total

1.  T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens.

Authors:  Michael A Brehm; Amelia K Pinto; Keith A Daniels; Jonathan P Schneck; Raymond M Welsh; Liisa K Selin
Journal:  Nat Immunol       Date:  2002-06-03       Impact factor: 25.606

2.  Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease.

Authors:  Nanda Kerkar; Kaushik Choudhuri; Yun Ma; Ayman Mahmoud; Dimitrios P Bogdanos; Luigi Muratori; Francesco Bianchi; Roger Williams; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

3.  Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients.

Authors:  E Kitazawa; T Igarashi; N Kawaguchi; H Matsushima; Y Kawashima; R W Hankins; H Miyakawa
Journal:  J Autoimmun       Date:  2001-11       Impact factor: 7.094

4.  Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.

Authors:  R Klein; U M Zanger; T Berg; U Hopf; P A Berg
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

Review 5.  The Guillain-Barré syndrome: a true case of molecular mimicry.

Authors:  C Wim Ang; Bart C Jacobs; Jon D Laman
Journal:  Trends Immunol       Date:  2004-02       Impact factor: 16.687

Review 6.  Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty?

Authors:  Urs Christen; Edith Hintermann; Martin Holdener; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2009-08-27       Impact factor: 7.094

7.  Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium.

Authors:  Carlo Selmi; David L Balkwill; Pietro Invernizzi; Aftab A Ansari; Ross L Coppel; Mauro Podda; Patrick S Leung; Thomas P Kenny; Judy Van De Water; Michael H Nantz; Mark J Kurth; M Eric Gershwin
Journal:  Hepatology       Date:  2003-11       Impact factor: 17.425

8.  A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens.

Authors:  T Sugimura; P Obermayer-Straub; A Kayser; S Braun; S Loges; B Alex; B Lüttig; E F Johnson; Michael P Manns; Christian P Strassburg
Journal:  Autoimmunity       Date:  2002-12       Impact factor: 2.815

9.  Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea.

Authors:  Christine A Kirvan; Susan E Swedo; Janet S Heuser; Madeleine W Cunningham
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

Review 10.  Induction, acceleration or prevention of autoimmunity by molecular mimicry.

Authors:  Urs Christen; Matthias G von Herrath
Journal:  Mol Immunol       Date:  2004-02       Impact factor: 4.407

View more
  7 in total

Review 1.  Immune mechanisms of Concanavalin A model of autoimmune hepatitis.

Authors:  Hai-Xia Wang; Man Liu; Shun-Yan Weng; Jing-Jing Li; Chao Xie; Hong-Lin He; Wen Guan; Yun-Sheng Yuan; Jin Gao
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

Review 2.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 3.  Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

Review 4.  The role of vitamin d in autoimmune hepatitis.

Authors:  Khanh Vinh Quoc Luong; Lan Thi Hoang Nguyen
Journal:  J Clin Med Res       Date:  2013-10-12

Review 5.  Medullary thymic epithelial cells and central tolerance in autoimmune hepatitis development: novel perspective from a new mouse model.

Authors:  Konstantina Alexandropoulos; Anthony J Bonito; Erica G Weinstein; Olivier Herbin
Journal:  Int J Mol Sci       Date:  2015-01-16       Impact factor: 5.923

6.  The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.

Authors:  Han Wang; Xinxia Feng; Ping Han; Yu Lei; Yujia Xia; Dean Tian; Wei Yan
Journal:  Mol Med Rep       Date:  2019-10-16       Impact factor: 2.952

Review 7.  Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients.

Authors:  Han Wang; Xinxia Feng; Wei Yan; Dean Tian
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.